GlassScriptPhysician profile
Jay Allen Milton Messer
NPI 1689038051
$10,740.73
in general payments reported to CMS, 2019-2025
33 companies · $8,521 in 2025
The $8,521 reported for 2025 was more than what 96% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2021: $18.22 · 2022: $407 · 2023: $609 · 2024: $788 · 2025: $8,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,513 · Food and Beverage: $2,912 · Consulting Fee: $2,494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,512.50 |
| Food and Beverage | $2,911.69 |
| Consulting Fee | $2,493.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $8,276.71 | 2024-2025 | Barrigel, Urolift |
| Janssen Biotech, INC. | $449.80 | 2024-2025 | Carvykti, Rybrevant, Erleada |
| Gt Medical Technologies, INC | $260.63 | 2022-2023 | Gammatile |
| Viewray Technologies INC | $166.58 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $165.48 | 2019-2023 | Lynparza |
| Boston Scientific Corporation | $132.53 | 2022-2023 | Spaceoar Vue System - 10ml |
| Progenics Pharmaceuticals, INC. | $123.46 | 2025 | |
| Bioprotect Medical, INC. | $115.26 | 2025 | Bioprotect Balloon Implant System |
| Merck Sharp & Dohme LLC | $107.40 | 2021-2023 | Keytruda, Lynparza |
| Isoray, INC | $106.18 | 2019 | |
| Dendreon Pharmaceuticals LLC | $86.40 | 2024-2025 | Provenge |
| Mirati Therapeutics, INC. | $68.90 | 2023-2024 | Krazati |
| Lilly USA, LLC | $62.22 | 2022-2024 | Jaypirca, Retevmo, Verzenio |
| Incyte Corporation | $61.79 | 2022-2023 | Jakafi |
| Genmab U.S., INC. | $59.59 | 2023 | Epkinly |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $57.07 | 2022 | |
| Blue Earth Diagnostics | $50.28 | 2024 | |
| Servier Pharmaceuticals LLC | $46.54 | 2023 | |
| Sumitomo Pharma America, INC. | $43.06 | 2025 | Orgovyx |
| Eisai INC. | $41.43 | 2023-2024 | |
| Daiichi Sankyo INC. | $25.79 | 2022 | |
| Spectrum Pharmaceuticals INC. | $25.13 | 2023 | Rolvedon |
| Novartis Pharmaceuticals Corporation | $24.84 | 2025 | |
| Apellis Pharmaceuticals, INC. | $21.81 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.79 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.68 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.42 | 2022 | |
| Immunogen, INC. | $19.14 | 2024 | Elahere |
| Karyopharm Therapeutics INC. | $17.73 | 2022 | |
| Pfizer INC. | $16.60 | 2024 | |
| Morphosys, US INC. | $16.34 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $16.05 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.10 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Messer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.